Biomedical Engineering Reference
In-Depth Information
7. Subramanian GM, Fiscella M, Lamouse-Smith A, Zeuzem S,
McHutchison JG. (2007) Albinterferon alpha-2b: a genetic
fusion protein for the treatment of chronic hepatitis C. Nat.
Biotechnol. 25(12), 1411-1419.
8. Zeuzem S, Sulkowski MS, Lawitz EJ, Rustgi VK, Rodriguez-
Torres M, Bacon BR, et al. (2010) Albinterferon Alfa-2b was
not inferior to PEGylated interferon-
a
in a randomized trial of
patients with chronic hepatitis C virus genotype 1. Gastroen-
terology 139(4), 1257-1266.
9. Nelson DR, Benhamou Y, ChuangW-L, Lawitz EJ, Rodriguez-
Torres M, Flisiak R, et al. (2010) Albinterferon Alfa-2b was
not inferior to PEGylated interferon-
a
in a randomized trial of
patients with chronic hepatitis C virus genotype 2 or 3.
Gastroenterology 139(4), 1267-1276.
10. Holt LJ, Basran A, Jones K, Chorlton J, Jespers LS, Brewis
ND, et al. (2008) Anti-serum albumin domain antibodies for
extending the half-lives of short lived drugs. Protein Eng. Des.
Sel. 21(5), 283-288.
11. Bendele A, Seely J, Richey C, Sennello G, Shopp G. (1998)
Short communication: renal tubular vacuolation in animals
treated with polyethylene-glycol-conjugated proteins. Toxicol.
Sci. 42(2), 152-157.
12. Malik DK, Baboota S, Ahuja A, Hasan S, Ali J. (2007) Recent
advances in protein and peptide drug delivery systems. Curr.
Drug Deliv. 4(2), 141-151.
13. Scallon B, Cai A, Solowski N, Rosenberg A, Song X-Y, Shealy
D, et al. (2002) Binding and functional comparisons of two
types of tumor necrosis factor antagonists. J. Pharmacol. Exp.
Ther. 301(2), 418-426.
14. Nestorov I. (2005) Clinical pharmacokinetics of TNF antago-
nists: howdo they differ? Semin. Arthritis Rheum. 34(5 Suppl. 1),
12-18.
15. Gomez-Reino JJ, Carmona L. (2006) Switching TNF antag-
onists in patients with chronic arthritis: an observational
study of 488 patients over a four-year period. Arthritis Res.
Ther. 8(1), R29.
16. Kohno T, Tam L-TT, Stevens SR, Louie JS. (2007) Binding
characteristics of tumor necrosis factor receptor-Fc fusion
proteins vs anti-tumor necrosis factor mAbs. J. Investig.
Dermatol. Symp. Proc. 12(1), 5-8.
17. Kast RE, Altschuler EL. (2004) Bone density loss in Crohn's
disease: role of TNF and potential for prevention by bupropion.
Gut 53(7), 1056.
18. Dubost JJ, Soubrier M, Ristori JM, Beaujon G, Oualid T,
Bussiere JL, et al. (1997) An open study of the anti-TNF alpha
agent pentoxifylline in the treatment of rheumatoid arthritis.
Rev. Rhum. Engl. Ed. 64(12), 789-793.
19. Qin C, Ding Y, Huang D, Xu J, Ma R, Huang J. (2011) Down-
regulation of TNF-alpha by small interfering RNA inhibits parti-
cle-induced inflammation in vitro. Artif. Organs 35(7), 706-714.
20. Deng G-M. (2007) Tumor necrosis factor receptor pre-ligand
assembly domain is an important therapeutic target in inflam-
matory arthritis. BioDrugs 21(1), 23-29.
21. Lansigan F, Stearns DM, Foss F. (2010) Role of denileukin
diftitox in the treatment of persistent or recurrent cutaneous
T-cell lymphoma. Cancer Manag. Res. 2, 53-59.
22. Rajvanshi P, Shulman HM, Sievers EL, McDonald GB. (2002)
Hepatic sinusoidal obstruction after gemtuzumab ozogamicin
(Mylotarg) therapy. Blood 99(7), 2310-2314.
23. Erickson HK, Widdison WC, Mayo MF, Whiteman K,
Audette C, Wilhelm SD, et al. (2010) Tumor delivery and
in vivo processing of disulfide-linked and thioether-linked
antibody-maytansinoid conjugates. Bioconjug. Chem. 21(1),
84-92.
24. Heisler I, Keller J, Tauber R, Sutherland M, Fuchs H. (2003) A
cleavable adapter to reduce nonspecific cytotoxicity of recom-
binant immunotoxins. Int. J. Cancer 103(2), 277-282.
25. Atkins MB, Kunkel L, Sznol M, Rosenberg SA. (2000) High-
dose recombinant interleukin-2 therapy in patients with meta-
static melanoma: long-term survival update. Cancer J. Sci. Am.
6(Suppl. 1), S11-14.
26. Rizzardi G, Traversari C, Valentinis B, Di Matteo P, Alberici
L, Cota M, et al. (2010) Contribution of NGR and TNF
portions of NGR-TNF to tumor vessel-specific homing
and apoptosis in vivo. ASCO Meeting Abstracts 28(15
suppl.), e13554.
27. Arap W, Pasqualini R, Ruoslahti E. (1998) Cancer treatment by
targeted drug delivery to tumor vasculature in a mouse model.
Science 279(5349), 377-380.
28. Silverman J, Liu Q, Lu Q, Bakker A, To W, Duguay A, et al.
(2005) Multivalent avimer proteins evolved by exon shuffling of
a family of human receptor domains. Nat. Biotechnol. 23(12),
1556-1561.
29. Nickerson-Nutter C, Tchistiakova L, Seth NP, Kasaian M,
Sibley B, Olland S, et al. (2011) Distinct in vitro binding
properties of the anti-CD20 small modular immunopharma-
ceutical 2LM20-4 result in profound and sustained in vivo
potency in cynomolgus monkeys. Rheumatology (Oxford)
50(6), 1033-1044.
30. Jain RK. (1990) Physiological barriers to delivery of mono-
clonal antibodies and other macromolecules in tumors. Cancer
Res. 50(3 Suppl.), 814s-819s.
31. Prior CP, Sadeghi H, Turner A. (2011) Oral delivery of modified
transferrin fusion proteins. US 2011/0091543 A1. US.
32. Dela Cruz JS, Trinh KR, Morrison SL, Penichet ML. (2000)
Recombinant anti-human HER2/neu IgG3-(GM-CSF) fusion
protein retains antigen specificity and cytokine function
and demonstrates antitumor activity. J. Immunol. 165(9),
5112-5121.
33. Corti A, Curnis F, Arap W, Pasqualini R. (2008) The neo-
vasculature homing motif NGR: more than meets the eye.
Blood 112(7), 2628-2635.
34. Michael NP, Chester KA, Melton RG, Robson L, Nicholas W,
Boden JA, et al. (1996) In vitro and in vivo characterisation of a
recombinant carboxypeptidase G2::anti-CEA scFv fusion pro-
tein. Immunotechnology 2(1), 47-57.
35. Bhatia J, Sharma SK, Chester KA, Pedley RB, Boden RW,
Read DA, et al. (2000) Catalytic activity of an in vivo tumor
targeted anti-CEA scFv::carboxypeptidase G2 fusion protein.
Int. J. Cancer 85(4), 571-577.
36. Orita I, Sakamoto N, Kato N, Yurimoto H, Sakai Y. (2007)
Bifunctional
enzyme
fusion of 3-hexulose-6-phosphate
Search WWH ::
Custom Search